

Datasheet: MCA709SBUV400

BATCH NUMBER 100006042

Description:	RAT ANTI HUMAN CD28:StarBright UltraViolet 400
Specificity:	CD28
Format:	StarBright UltraViolet 400
Product Type:	Monoclonal Antibody
Clone:	YTH913.12
Isotype:	lgG2b
Quantity:	100 TESTS/0.5ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	•			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human		
Product Form	Purified IgG conjugate	ed to StarBright UltraV	/iolet 400 - liquid
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm
	StarBright UltraViolet 400	347	394
eparation	Purified IgG prepared supernatant	by affinity chromatog	raphy on Protein G
fer Solution	Phosphate buffered sa	aline	
eservative	0.09% Sodium Azide	(NaN ₃)	
abilisers	1% Bovine Serum Alb	umin	
	0.1% Pluronic F68		
	0.1% PEG 3350		

Immunogen

Human peripheral blood T-cells

External Database Links

UniProt:

P10747 Related reagents

Entrez Gene:

940 CD28 Related reagents

Fusion Partners

Spleen cells from an immunised DA rat were fused with cells of the Y3/Ag 1.2.3 rat myeloma cell line

Specificity

Rat anti Human CD28 antibody, clone YTH913.12 recognizes human CD28, a ~44 kDa single pass type 1 trans-membrane protein expressed as a homodimer on a major subset of human T-cells (<u>Thompson et al. 1989</u>), responsible for activation of these cells via interaction with the TCR. CD28 is involved in the tuning of the T-cell for activation via TCR, lowering the threshold for activation from around 8000 triggered TCRs to approximately 1500 (<u>Viola et al.1996</u>).

CD28 along with CD152, also known as CTLA-4 acts as a co-receptor for the co-stimulatory molecules CD80 and CD86 (<u>Azuma et al. 1993</u>). CD28 offers a positive stimulatory role on ligation of CD80 and CD86 while CTLA-4 offers a negative feedback signal preventing CD28 mediated T-cell activation of CD86 (<u>Krummel et al. 1995</u>).

Rat anti human CD28, clone YTH913.12 has been reported to recognize an epitope of CD28 expressed by NK cells, which is not recognized by other anti human CD28 clones such as 9.3 and CD28.2 (<u>Galea-Lauri et al 1999.</u>) Other reports however have failed to demonstrate CD28 staining on peripheral blood derived NK cells using clone YTH913.12 (Wilson et al. 1999).

Flow Cytometry

Use 5ul of the suggested working dilution to label 10⁶ cells in 100ul. Best practices suggest a 5 minutes centrifugation at 6,000g prior to sample application.

References

- 1. Reiter, C. (1989) Cluster Report: CD28 in Leucocyte Typing IV: White Cell Differentiation Antigens. Edited by Knapp, W., Dorken, B., Gilks, W.R., Rieber, E.P., Schmidt, R.E., Stein, H. and von dem Borne, A.E.G.Kr. Oxford University Press. pp 352-3.
- 2. McLeod, J.D. *et al.* (1998) Activation of human T cells with superantigen (staphylococcal enterotoxin B) and CD28 confers resistance to apoptosis via CD95. <u>J Immunol.</u> 160: 2072-9.
- 3. Galea-Lauri, J. *et al.* (1999) Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells. <u>J Immunol. 163 (1)</u>: 62-70.
- 4. Wilson, J.L. *et al.* (1999) NK cell triggering by the human costimulatory molecules CD80 and CD86. <u>J Immunol.</u> 163: 4207-12.
- 5. Costa, C. *et al.* (2002) Human NK cell-mediated cytotoxicity triggered by CD86 and Gal alpha 1,3-Gal is inhibited in genetically modified porcine cells. <u>J Immunol. 168: 3808-16.</u>

- 6. Ponchel, F. *et al.* (2002) Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood. 100: 4550-6.
- 7. Blanco, B. *et al.* (2003) Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. <u>J Immunol.</u> 171: 1070-7.
- 8. Goodier, M.R. and Londei, M. (2004) CD28 is not directly involved in the response of human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells. Immunology. 111: 384-90.
- 9. Gabdoulkhakova, A. *et al.* (2007) High rate of mutation reporter gene inactivation during human T cell proliferation. Immunogenetics. 59: 135-43.
- 10. Kropf, P. *et al.* (2007) Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. <u>Eur J Immunol. 37: 935-45.</u>
- 11. Pridgeon, C. *et al.* (2011) Regulation of IL-17 in chronic inflammation in the human lung. Clin Sci (Lond). 120: 515-24.
- 12. Litjens, N.H. *et al.* (2011) Identification of Circulating Human Antigen-Reactive CD4+FOXP3+ Natural Regulatory T Cells. J Immunol. 188: 1083-90.
- 13. Svensson-Arvelund, J. *et al.* (2015) The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages. J Immunol. 194 (4): 1534-44.
- 14. Hasib, L. *et al.* (2016) Functional and homeostatic defects of regulatory T cells in patients with coronary artery disease. <u>J Intern Med. 279 (1): 63-77.</u>
- 15. Siska, E.K. *et al.* (2017) Generation of an immortalized mesenchymal stem cell line producing a secreted biosensor protein for glucose monitoring. <u>PLoS One. 12 (9):</u> <u>e0185498.</u>
- 16. Hellberg, S. *et al.* (2021) Progesterone Dampens Immune Responses in *In Vitro* Activated CD4⁺ T Cells and Affects Genes Associated With Autoimmune Diseases That Improve During Pregnancy. <u>Front Immunol. 12: 672168.</u>

Storage	Store at +4°C. DO NOT FREEZE. This product should be stored undiluted.
Guarantee	12 months from date of despatch
Acknowledgements	This product is covered by U.S. Patent No. 10,150,841 and related U.S. and foreign counterparts
Health And Safety Information	Material Safety Datasheet documentation #20471 available at: https://www.bio-rad-antibodies.com/SDS/MCA709SBUV400 20471
Regulatory	For research purposes only

Related Products

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)
 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

Fax: +1 919 878 3751 Fax: +44 (0)1865 852 739 Fax: +49 (0) 89 8090 95 50 To

Email: antibody_sales_us@bio-rad.com Email: antibody_sales_uk@bio-rad.com Email: antibody_sales_de@bio-rad.com

batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M392289:211029'

Printed on 08 Mar 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint